Changes in Hong Kong stocks | Yidu Technology (02158) rose more than 16% for the first time, AI-assisted diagnosis was included in health insurance YiDuCore to enable the implementation of full-scenario solutions

The Zhitong Finance App learned that Yidu Technology (02158) rose more than 16%. As of press release, it had risen 16.16% to HK$5.68, with a turnover of HK$152 million.

According to the news, on November 23, the National Health Insurance Administration held a press conference to explain 17 batches of price proposals. The National Health Insurance Administration said that in order to support the entry of relatively mature artificial intelligence assistive technology into clinical application and prevent additional burden on patients, the National Health Insurance Administration analyzed potential application scenarios of artificial intelligence and established “artificial intelligence assistance” extensions in radiology, ultrasound, and rehabilitation projects. That is, at the same price level, hospitals can choose to train medical personnel for diagnosis and treatment, or choose to use artificial intelligence to participate in diagnosis and treatment, but there are no repeated charges at this stage.

The company recently announced its mid-term results for fiscal year 2025, achieving total revenue of RMB 329 million during the period. Losses during the period were reduced to RMB 56.36 million, a year-on-year loss reduction of 29.2%, and cash flow continued to be optimized and improved. As a leader in the domestic AI medical industry, Yidu Technology continued to invest in artificial intelligence technology during the reporting period, especially the development and commercialization of self-developed medical language models, and promoted the implementation of AI in specific scenarios. Everbright Securities pointed out that considering the implementation of Yiducore's all-scenario enabling AI medical intelligent brain solution, adjusted EBITDA continued to be profitable and maintained a “buy” rating.